07.01.2013 Views

Sorted By Test Name - Mayo Medical Laboratories

Sorted By Test Name - Mayo Medical Laboratories

Sorted By Test Name - Mayo Medical Laboratories

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

TACIG<br />

89122<br />

Interpretation: An interpretive report is provided that describes the mutation(s), if any, their potential<br />

clinical significance, and whether they have been previously reported or are new mutations. Variants of<br />

unknown clinical significance also will be documented in the report. The published mutations in the TACI<br />

gene are a combination of missense, nonsense, small insertion or deletion, and other point mutations, all<br />

of which will be detected by full gene sequencing.<br />

Reference Values:<br />

An interpretive report will be provided.<br />

Clinical References: 1. Mackay F, Ambrose C: The TNF family members BAFF and APRIL: the<br />

growing complexity. Cytokine Growth Factor Rev 2003;14:311-324 2. Mackay F, Schneider P, Rennert<br />

P, Browning J: BAFF and APRIL: a tutorial on B cell survival. Ann Rev Immunol 2003;21:231-264 3.<br />

Castigli E, Geha RS: Molecular basis of common variable immunodeficiency. J Allergy Clin Immunol<br />

2006;117:740-746 4. Castigli E, Wilson S, Garibyan L, et al: Reexamining the role of TACI coding<br />

variants in common variable immunodeficiency and selective IgA deficiency. Nat Genet<br />

2007;39(4):429-431 5. Salzar U, Chapel HM, Webster ADB, et al: Mutations in TNFRSF13B encoding<br />

TACI are associated with common variable immunodeficiency in humans. Nat Genet 2005;37(8):820-828<br />

6. Castigli E, Wilson SA, Garibyan L, et al: TACI is mutant in common variable immunodeficiency and<br />

IgA deficiency. Nat Genet 2005;37(8):829-834 7. Scharenberg AM, Hannibal MC, Torgerson T, et al:<br />

Common variable immunodeficiency overview. Gene Reviews 2006, Posted July 5, 2006<br />

http://www.genetests.org/profiles/cvid<br />

Transmembrane Activator and CAML Interactor (TACI) Gene,<br />

Known Mutation Analysis<br />

Clinical Information: Transmembrane activator and CAML interactor (TACI) is a member of the<br />

tumor-necrosis factor (TNF)-like receptor family, a group of receptors that regulate both survival and<br />

apoptosis of immune cells.(1) TACI is expressed on the surface of resting B cells and activated T cells,<br />

but not resting T cells. TACI interacts with 2 ligands-BAFF (B-cell activating factor), also known as<br />

BLys (B-lymphocyte stimulator), which belongs to the TNF family, and APRIL (a proliferation-inducing<br />

ligand). The ligands for TACI are expressed on macrophages, monocytes, and dendritic cells.(1) TACI<br />

regulates isotype class-switching of immunoglobulins and also is involved in the antibody response to<br />

T-independent antigens.(2) TACI is encoded by the TACI gene (official symbol, TNFRSF13B). The<br />

human TACI gene locus is located on the short arm of chromosome 17, which is a common target for<br />

mutation and rearrangement.(2) The TACI gene consists of 5 exons spanning approximately 35 kb<br />

(including 1002 bp upstream of the 5' untranslated region [UTR] and 1024 bp downstream of the 3' UTR).<br />

The mRNA length is 1377 bp, encoding for a 294-amino acid protein with a molecular weight of 32.34<br />

kD. Six mutations (D68X [also called L69fsX11], C104R, S144X, A181E, S194X, and R202H) were<br />

identified in the TACI gene in the original reports.(3,4) Of these 6 mutations, 4 (D68X, C104R, A181E,<br />

and R202H) have been shown to be statistically significant in common variable immunodeficiency<br />

(CVID) and selective IgA deficiency (sIgAD) patients, when compared to controls.(5) Several other<br />

mutations have been reported, but none of these appear to be statistically significant when compared to<br />

controls.(5) Two other mutations, P251L and V220A, are considered to be rare polymorphisms as they are<br />

present in both controls and patients.(3-5) The TACI mutations described so far are nonsense, missense,<br />

or frameshift (due to the insertion of a single extra nucleotide) mutations, all of which can be detected by<br />

gene sequencing. No large deletions or duplications have been reported for this gene at this time. TACI<br />

mutations account for 8% to 15% of CVID cases depending on the study population and are sporadic in<br />

the majority of cases. The familial TACI mutations can be inherited in either an autosomal dominant or<br />

autosomal recessive fashion. There also appears to be variable penetrance in the familial TACI<br />

mutations.(7) TACI mutations appear to be strongly associated with lymphoproliferative diseases such as<br />

splenomegaly or tonsillar hypertrophy. Autoimmune thyroiditis is observed in 15% of TACI<br />

mutation-positive CVID cases. The incomplete penetrance seen for TACI mutations indicates that a<br />

mutation can be present, but the individual does not develop the disease phenotype. The known TACI<br />

mutations appear, in most cases, to be associated with normal protein expression with aberrant or absent<br />

functional activity and require gene sequencing analysis to confirm the presence of the mutation as well as<br />

correlation with the clinical phenotype.<br />

Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or <strong>Mayo</strong><strong>Medical</strong><strong>Laboratories</strong>.com Page 1779

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!